|Bid||36.01 x 1200|
|Ask||36.02 x 2200|
|Day's Range||35.98 - 36.16|
|52 Week Range||28.43 - 37.30|
|PE Ratio (TTM)||32.56|
|Forward Dividend & Yield||1.40 (3.85%)|
|1y Target Est||39.09|
Pascal Soriot, AstraZeneca CEO, speaks to CNBC's Meg Tirrell at American Society of Clinical Oncology (ASCO) conference about the company's immunotherapy treatments, research and development and his thoughts on drug pricing.
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. This has led to an increase in merger & acquisition activity and may boost innovation and capital building in the biotech industry. Earlier in the year, we have seen Sanofi SA (NYSE:SNY) and Celgene Corporation (NASDAQ:CELG) acquiring smaller biotech companies.
AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.
have discontinued late-stage trials of their experimental Alzheimer's disease drug lanabecestat, sending both companies' stock prices down Tuesday. AstraZeneca's stock fell 22 cents to close at $36.16 a share, while Lilly dropped 35 cents to $85.49. "The complexity of Alzheimer's disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from the devastating disease," Dr. Daniel Skovronsky, president of Lilly Research Labs, said in the statement.
AstraZeneca and Eli Lilly became the latest Tuesday in a series of firms to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.
Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease. The treatment, lanabecestat, belongs to a class of drugs called beta secretase cleaving enzyme (BACE) inhibitor, that blocks an enzyme involved in the production of a protein that creates brain plaques, considered a major cause of the disease. Experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures, with Johnson and Johnson last month stopping mid-stage trials testing its BACE inhibitor drug.
Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness. An independent data monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.
AstraZeneca and Eli Lilly are to halt a global trial of a drug meant to treat people suffering from early and mild forms of Alzheimer’s disease after a panel found the treatment was unlikely to meet its ...
AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.
In the second half of fiscal 2018, major news is expected for indications in diabetes, anemia, COPD (chronic obstructive pulmonary disease), and lupus in AstraZeneca’s (AZN) pipeline. A data readout is expected from the DECLARE trial for Farxiga for type 2 diabetes, and a regulatory decision in the European Union is expected for the Bydureon autoinjector for type 2 diabetes.
Investors have a lot to watch for in AstraZeneca’s (AZN) research pipeline in the second fiscal quarter. The company expects a data readout for Lynparza in an ovarian cancer indication. A regulatory decision is expected for Tagrisso in the European Union for lung cancer.
In the first quarter, AstraZeneca’s (AZN) cash outflow from operating activities rose YoY (year-over-year) to $140 million from $88 million, due to an increase in the movement of working capital and higher short-term provisions for the launch of new medicines. AstraZeneca generated $273 million from investing activities in the first quarter, compared with $146 million in Q1 2017. This change was due to lower capital expenditure and the timing of receipts on disposal of intangible assets.
AstraZeneca (AZN) has maintained its guidance for fiscal 2018. This expected growth in product sales is weighted towards the second half of the year, reflecting the impact of generic competition for Crestor in Europe and Japan and an increased revenue contribution from new medicines. AstraZeneca expects the sum of externalization revenue and other operating income and expenses to fall YoY (year-over-year).
In the first quarter, AstraZeneca’s (AZN) sales were boosted by strong product launches and newer medicines and partially offset by a decrease in Crestor sales. AstraZeneca’s total revenue fell 4% YoY (year-over-year) to $5.2 billion in Q1 2018. AstraZeneca expects to return to growth in fiscal 2018.
Investors have a lot to watch for when it comes to AstraZeneca (AZN) stock, with key events expected in the company’s research pipeline and higher uptake expected for the company’s new medicines on the market. In this series, we’ll explore what analysts think of AstraZeneca’s stock potential, financial performance, valuation, and more. Of the six analysts covering AstraZeneca, four have recommended “buy” or a higher rating, while two have recommended “hold.” Their mean rating for the stock is 1.8, and their target price is $39.09.
NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ingersoll-Rand ...
NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma's internal CNS pipeline. On May 7, Luye licensed exclusive rights to market the dibenzothiazepine atypical antipsychotic and its extended-release formulation, Seroquel XL, in 51 countries spanning developed and emerging markets. While Luye already markets products in developed and some emerging markets such as Russia and Indonesia, the deal will give Luye access to additional emerging markets including Mexico, Brazil, Saudi Arabia and South Africa.
SHANGHAI , June 6, 2018 /PRNewswire/ -- The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial ...
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data, which showed clinical improvement in median radiologic progression-free survival with LYNPARZA® in combination with abiraterone compared to abiraterone monotherapy, a current standard of care, in metastatic castration-resistant prostate cancer .
Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until the prior month that BIIB stock began to recover from its mess.
As discussed earlier, Novartis (NVS) reported EPS of $1.28 and revenue of $12.7 billion in the first quarter. In the second quarter, its revenue is expected to rise 7.8% year-over-year to $13.2 billion from $12.2 billion. The chart below shows analysts’ recommendations for Novartis over the last 12 months.